A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
for T-cell Acute Lymphoblastic Leukemia
13 locations incl. Duarte
Sponsor: Wugen, Inc.
Sex: All·Age: 1+
Code: NCT06514794·Phase 2·Recruiting